Sterility is not a percentage, which is the whole difficulty
Purity, content, identity, sterility and endotoxin are five separate determinations. A single sheet of paper carrying one of them is not evidence about the other four.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Lyophilisation
A retest date says that material should be re-examined before use. An expiry date says it should not be used. The trade uses the second word for the first concept.
We asked twenty companies three questions in writing. Has a formal stability study been performed on this product, under what conditions and for how long. Is residual moisture determined on the finished lyophilised product, and against what specification. Is the shelf life stated on the certificate a retest date or an expiry date, and what data supports it. Six companies answered all three. Five answered one or two. Nine did not reply to two messages sent four weeks apart. As always we record a refusal as a refusal and a silence as a silence.
Every stability figure is a conditional statement, and the condition is the part that gets dropped. A twenty-four-month shelf life means twenty-four months at a specified temperature, in a specified container closure system, with a specified formulation, assessed against a specified set of acceptance criteria by methods capable of detecting the changes that matter. Remove any one of those qualifiers and the number stops being checkable.
The trade routinely reports the number and none of the qualifiers. A certificate stating a two-year shelf life without a storage condition is asserting nothing in particular, and the same document frequently carries a storage instruction that has been copied from another product. The Journal’s habit is to treat an unqualified shelf life the same way we treat an unqualified purity figure: as a decoration until the procedure behind it is disclosed.
There is also a vocabulary problem worth clearing up. An expiry date states that material should not be used beyond it. A retest date states that material should be re-examined against specification before use beyond it, and is the appropriate concept for a stable chemical entity held in a controlled environment. Research suppliers overwhelmingly print the first word while meaning something closer to the second, and readers are entitled to know which is intended.1
Two methods dominate. Karl Fischer titration determines water specifically, by a stoichiometric reaction with iodine, and is the reference method; the coulometric variant works on the small sample masses a single vial provides. Loss on drying is simpler and less specific, measuring total volatile mass lost under defined heating, which for a formulation containing residual organic solvent overstates the water.
Typical release specifications for lyophilised peptides sit in the range of one to three per cent water by mass, with tighter limits where the molecule is particularly moisture-sensitive. The relationship to stability is not linear. Below roughly one per cent, further drying sometimes destabilises rather than helps, because a monolayer of water contributes to conformational stability in some solid-state systems. Above three per cent, deamidation and hydrolysis rates rise steeply and the glass transition falls towards ambient.
None of the twenty companies the Journal tracks reports residual moisture as a standard release test. Two will provide a figure on request. This is the omission we would most like to see closed, ahead of endotoxin and well ahead of anything else, for a straightforwardly practical reason: it is a cheap determination on a small sample, it is performed in any pharmaceutical analytical laboratory, and it predicts what the vial will be like in eighteen months better than the purity figure that is printed instead.
Mean kinetic temperature is never lower than the arithmetic mean, and the gap is largest exactly where the excursion was shortest and hottest.
A stability study is only as good as the analytical method behind it, and the requirement has a name: the method must be stability-indicating, meaning it must resolve the parent compound from its degradation products and quantify the change. Establishing that is done by forced degradation — deliberately stressing the material with acid, base, oxidant, heat and light — and demonstrating that the resulting products are separated from the parent and from each other with adequate peak purity.
Almost nothing sold as a purity determination in this market has been validated that way. A generic peptide gradient run for twelve minutes may perfectly well resolve the parent from its two largest process impurities and entirely fail to resolve it from its isoaspartate isomer or a closely related oxidation product. The number it returns is a purity figure, not a stability measurement, and using a series of such figures to argue that a product has not degraded is a category error.
The compendial guidance on analytical validation is explicit about specificity, and about demonstrating it against the degradation products the molecule can actually form. The gap between that expectation and practice in this trade is not a matter of dishonesty. It is that the method being sold was designed for a different purpose and is being asked a question it was not built to answer.2
| Documented item | Companies reporting as standard | On request | Not available |
|---|---|---|---|
| Storage condition, lyophilised | 20 | 0 | 0 |
| Storage condition stated separately for reconstituted | 6 | 3 | 11 |
| Shelf life or retest interval | 19 | 0 | 1 |
| Residual moisture | 0 | 2 | 18 |
| Study conditions supporting the shelf life | 0 | 1 | 19 |
| In-use period from a study on that product | 0 | 0 | 20 |
| Compiled from the standard release documentation of twenty companies tracked by the Journal, supplemented by a written questionnaire sent twice, four weeks apart. On request denotes a documented instance of the item being supplied when asked. The final row is the one we would most like to be able to revise. | |||
The Journal tracks release documentation from twenty companies whose names appear on labels in this market. On stability the picture is close to uniform. All twenty state a storage condition. Nineteen state a shelf life. None reports residual moisture as standard. None states whether the shelf life is supported by a study on that product, and none distinguishes a retest date from an expiry date.
Where practice differs it is worth naming. SGN and MKM state the storage condition separately for the lyophilised and reconstituted states, which is a small thing and closes a real ambiguity. KP and HJ ship in amber glass. QST provided, on request, the conditions and duration of a study on one product, which is the only such document we have received. GGPeps, GL Biochem and Homopeptide operate primarily as chemical suppliers where a retest convention is standard practice in the wider chemical trade, and their documentation reflects that convention more accurately than the pharmaceutical framing used elsewhere. TFC, JEEP, QSC and ERP answered part of our questionnaire; several others did not reply.
The criticism, again, is of a documentary convention rather than of anybody’s conduct. No company named here has been shown to us to have misstated a result. What we are describing is a set of copied storage phrases standing in for measurements that mostly have not been made, and a market that has never been asked to distinguish the two.
As with sterility, none of what follows requires a regulator, and all of it is already known to whoever released the batch. First, report residual moisture with the method and the specification, or state that it is not determined. Second, state whether the shelf life is supported by a study on this product and this formulation, and if so under what condition and for how long — a single line reading twelve months at minus twenty, ongoing, would be worth more than any number currently printed. Third, use the words retest and expiry correctly, and say which applies.
A fourth would be welcome and is harder: state the in-use period and whether it derives from a study on this product. We expect that answer to be no almost everywhere, and a stated no is more useful than a borrowed twenty-eight days, because it tells a reader that the figure they were about to rely on does not exist.
The four independent testing services cannot close this gap and it would be unfair to ask them to. Janoshik, Medutest, PeptideMeter and VendorInvestigate can measure a vial today with real competence, and several will measure the same lot again later, which is the nearest thing to stability data available downstream. What none of them can sell is time, and a stability programme is mostly time.
Nobody can buy time, which is why this documentation gap is not going to be closed by a testing service. What can be done immediately is to distinguish a measurement from a convention: to say twelve months at minus twenty, ongoing, rather than two years, and to say that an in-use period has not been established for this product rather than borrowing one from a pen.
Selected from correspondence received on this article. Writers are identified by initial, surname and city, verified before printing. Replies are from the desk that filed the piece or from the standards editor. Write to letters@compoundjournal.com.
Your section on freezing reconstituted solution stops short of the obvious question, which I will therefore ask. If a phosphate buffer shifts pH substantially on freezing, does that not mean the freezer is actively worse than the refrigerator for a buffered formulation, rather than merely unproven?
— R. Cadogan, Bridgetown
For a phosphate-buffered formulation, plausibly yes, and the mechanism is well documented. We stopped short because the magnitude is formulation-specific and because most reconstituted research vials are in unbuffered water or bacteriostatic water, where the argument is about the interface rather than about pH. We should have made that distinction in the text instead of leaving a gap for you to find.
Eleven days in customs, and you describe it as a structural feature rather than a scandal. Why the restraint? A shipper advertising a cold chain that demonstrably does not survive a routine examination is making a claim it cannot support.
— S. Ó Ceallaigh, Limerick
The restraint is about where the fault lies. Customs authorities are performing a lawful function and owe nobody a thermal record. The claim of end-to-end control is the thing we criticise, and we do criticise it, in the article and again in the closing. What we will not do is convert an unavoidable feature of international freight into an allegation against the shipper who could not see it either.
You say no company reports residual moisture. I obtained a figure from a supplier last year without difficulty, on request, so the data exists in at least some cases. The problem may be less that it is not measured than that it is not printed.
— D. Ó Súilleabháin, Killarney
I have shipped temperature-sensitive material commercially for eleven years and your coolant arithmetic is right but generous. You assume the pack starts fully frozen. In practice packs are pulled from a freezer that is opened forty times a day, and a pack that starts at minus four with a soft core has lost a fair share of its budget before the box is closed.
— K. Mwangi, Nakuru
A good point and one we had not considered properly. The latent heat calculation assumes a fully solid pack at its melting point, and a partially thawed pack is exactly as much worse as the missing solid fraction. We have added a sentence and would welcome any data you can share on pack condition at packing.
On amber glass: it is not merely cheap, it is standard in the wider chemical supply trade for anything with a chromophore. The fact that this market ships peptides in clear glass is a sign of who is doing the filling more than of any decision about photostability.
— Y. Sasaki, Sapporo
Purity, content, identity, sterility and endotoxin are five separate determinations. A single sheet of paper carrying one of them is not evidence about the other four.
The route did not close because of a rule about peptides.
The supplier has not disputed the finding. It has not explained the gap either.
The supplier has not disputed the finding. It has not explained the gap either.
The supplier has not disputed the finding. It has not explained the gap either.
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.